Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Harbin Gloria Pharmaceuticals Co., Ltd specializes in the development and manufacturing of generic and specialty pharmaceuticals, primarily focusing on the Chinese market. The company has a competitive edge through its extensive product portfolio, including over 100 generic drugs and a strong pipeline of new products, which positions it well in a rapidly evolving healthcare landscape.
Harbin Gloria generates revenue through the sale of generic and specialty drugs, leveraging its established distribution network across China. The company benefits from strong pricing power due to its extensive product range and established relationships with healthcare providers, allowing it to maintain healthy margins despite competitive pressures.
Regulatory approvals for new drug launches
Market share changes in the Chinese pharmaceutical sector
Pricing strategies in response to competition
Changes in healthcare policy affecting drug reimbursement
Regulatory changes that could impact drug approval processes
Technological advancements in drug development that could outpace current capabilities
Intensifying competition from both local and international generic manufacturers
Potential for price erosion in key therapeutic areas
Low liquidity risk due to minimal debt levels
Potential risks associated with reliance on a limited number of key products
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but overall healthcare spending can be influenced by GDP growth and consumer spending.
Low - The company has minimal debt, so rising interest rates do not significantly impact financing costs. However, higher rates could affect consumer spending on healthcare.
minimal - The company's low debt levels reduce its exposure to credit conditions.
value - Investors may be attracted to the company's low debt levels and strong cash flow generation despite recent revenue declines.
moderate - The stock has shown historical volatility, with a beta of approximately 1.2, indicating sensitivity to market movements.
